MORE►
therapeutics
Left: Milan Radovich, SVP and Chief Scientific Officer at Caris Life Sciences; Right: Boris L. Zaïtra, Head of Roche Corporate Business Development [Photos: LinkedIn/Roche]
North Texas’ Caris Life Sciences To Collaborate With Genentech on Novel Therapeutic Targets for Cancers
by Sandra Engelland | Dec 17, 2025
Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales payments, as well as potential tiered royalties on net sales of collaboration therapies, the company said.
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
